California-based biopharmaceutical company Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on Friday that Roche (SWX:ROG), a Switzerland-based healthcare company, has received approval for OCREVUS ZUNOVO (ocrelizumab and hyaluronidase-ocsq) with Halozyme's ENHANZE drug delivery technology from US Food and Drug Administration (FDA).
The combination is intended for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) as a twice-a-year, approximately 10-minute subcutaneous (SC) injection to be administered by a healthcare practitioner.
The FDA approval is based on pivotal data from the Phase III OCARINA II trial, which showed non-inferior levels of OCREVUS in the blood when administered subcutaneously and a safety and efficacy profile comparable to the intravenous (IV) formulation in people with RMS and PPMS.
Dr Helen Torley, Halozyme president and CEO said that now that the subcutaneous formulation of OCREVUS, OCREVUS ZUNOVO, which contains our ENHANZE drug delivery technology, is now approved in the US for patients with these two forms of multiple sclerosis, there will be greater treatment flexibility and optionality for patients with multiple sclerosis and their healthcare providers.
NCI reports IND submission for pilot study of Senhwa Biosciences Inc's developed Pidnarulex
Epitomee Medical's Capsule cleared by FDA for weight management
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Roche's OCREVUS ZUNOVO with Halozyme's ENHANZE drug delivery technology receives FDA approval
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Neuspera Medical names new chief operating officer
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024